Divincell : Technologie

PEP-NP™ Targeting System

DIVINCELL’s PEP-NP™ peptide nanoparticle system is designed to deliver RNA to the true source of disease—mutated or deleted genes that drive pathology, not just their secondary effects. By custom-selecting targeting peptides (using AI and experimentation), we enable efficient, repeatable delivery, bypassing off-target toxicity, immune barriers, and downstream signaling traps.

Targetable to organs, tissues, and cells at the genetic origin of disease
Bypasses endosomal entrappment relying on a novel mechanism for cell entry
Bypasses liver entrappment unless specifically targeted to the liver
Ensures repeated, safe dosing for a broad range of nucleic acid molecules without immunogenicity

A best-in-class nucleic acid delivery platform

Tumor Suppressor Rescue (TSG-RESCUE™, TSG-RESQ™)

Restores the lost function of mutated tumor suppressor genes like p53, the “Guardian of the Genome,” the most broadly mutated Tumor Suppressor occurring in 50% of all cancers, a major driver, and a marker of poor prognosis, with no successful targeting strategy for approximately 400,000 new individuals every year in the US alone.

Our technology delivers functional RNA exactly where it’s needed, preventing redundancy and resistance.

This new therapeutic approach to treat p53 mutations and alterations results in strong inhibition and regression of tumors in animal models as a single-agent therapy as well as in combination with other cancer therapies.

Our strategy can lead to a broad pipeline first targeting p53 and then moving to other Tumor Suppressors.

In vivo CAR T (PEP-CAR™)

Chimeric Antigen Receptor (CAR) T cell therapy has revolutionized hematologic cancer treatment and shows promise for autoimmune diseases, but ex vivo CAR T faces challenges including complex manufacturing, scalability issues, high costs, and safety concerns from lymphodepletion.

In vivo CAR T generation with lentiviral or lipid nanoparticle vectors expands accessibility but is limited by challenges in repeat dosing due to immunogenicity and liver toxicity. Aanastra’s peptide-based nanocarrier PEP-CAR™, targeting CD3 receptors, enables efficient in vivo engineering of T cells to express anti-CD19 CAR with demonstrated efficacy in mice—rapid depletion of CD19+ B cells and safe, repeated dosing for long-term therapy.

PEP-CAR™ offers a scalable, accessible alternative likely to surpass ex vivo approaches, with broad applicability in hematologic cancers and autoimmune diseases, and flexible targeting potential beyond CD19 to expand immune cell therapies.

Technology

Modal Heading